A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers

NCT ID: NCT04798638

Last Updated: 2022-12-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-04-30
• Study Completion Date: 2021-09-09

Brief Summary

To assess the pharmacokinetics of TY-9591 tablets and Osimertinib Mesylate tablets after a single fasting administration and the effect of food on the pharmacokinetics of TY-9591 tablets in healthy volunteers.

Detailed Description

This is a single center, randomized, open label, two phases study in healthy adult volunteers. The first phase is a two-sequence, two-period crossover trial. The volunteers will be randomly distributed into two groups and given either TY-9591 tablets or Osimertinib Mesylate tablets on a single fasting administration. In the second phase, all volunteers will be administrated TY-9591 tablets after a high fat meal. The washout between each treatment is no less than 21 days.

Conditions

Healthy Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm1: TY-9591 + Osimertinib + TY-9591

Participants will receive TY-9591 tablets under fasted condition in period 1 , followed by Osimeritinib Mesylate tablet under fasted condition in period 2. In period 3, participants will receive TY-9591 tablet in fed state (high-fat meal). The washout will be no less than 21 days between each treatment.

Group Type: EXPERIMENTAL

TY-9591 Tablets under Fasted Condition - Arm1

Intervention Type: DRUG

Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.

Osimertinib Mesylate Tablets under Fasted Condition - Arm1

Intervention Type: DRUG

Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.

TY-9591 Tablets after a High-fat Meal - Arm1

Intervention Type: DRUG

Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.

Arm2: Osimertinib + TY-9591 + TY-9591

Participants will receive Osimeritinib Mesylate tablet under fasted condition in period 1 , followed by TY-9591 tablets under fasted condition in period 2. In period 3, participants will receive TY-9591 tablet in fed state (high-fat meal). The washout will be no less than 21 days between each treatment.

Group Type: EXPERIMENTAL

Osimertinib Mesylate Tablets under Fasted Condition - Arm2

Intervention Type: DRUG

Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.

TY-9591 Tablets under Fasted Condition - Arm2

Intervention Type: DRUG

Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.

TY-9591 Tablets after a High-fat Meal - Arm2

Intervention Type: DRUG

Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.

Interventions

TY-9591 Tablets under Fasted Condition - Arm1

Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.

Intervention Type: DRUG

Osimertinib Mesylate Tablets under Fasted Condition - Arm1

Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.

Intervention Type: DRUG

TY-9591 Tablets after a High-fat Meal - Arm1

Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.

Intervention Type: DRUG

Osimertinib Mesylate Tablets under Fasted Condition - Arm2

Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.

Intervention Type: DRUG

TY-9591 Tablets under Fasted Condition - Arm2

Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.

Intervention Type: DRUG

TY-9591 Tablets after a High-fat Meal - Arm2

Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.

Intervention Type: DRUG

Other Intervention Names

TY-9591; AZD9291; TY-9591; AZD9291; TY-9591; TY-9591

Eligibility Criteria

Inclusion Criteria

1. Male must be ≥ 18 and ≤ 55 years of age.

2. Bodyweight of male must be ≥ 50.0 kg (bodyweight of female must be ≥ 45.0 kg), and the Body Mass Index must be ≥ 19.0 and ≤26.0 kg/m2.

3. The participants must have no birthing plan and agree to take adequate non-drug contraceptive measures within 2 weeks before screening to 6 months after the last drug treatment.

4. The participants have good communications with investigators, understand and comply with all requirements and fully understand and sign the informed consent form.

5. The results of physical examination, vital signs, ECG, laboratory examination and other relevant examination should compliance with the clinical protocol, or they will be recognized as non-clinical signs (NCS) if beyond the regulated range.

Exclusion Criteria

1. The participants who smoked daily >5 sticks of cigarette 3 months prior to screening or cannot give up smoking during study.

2. The participants consumed more than 14 units of alcohol per week (1 unit = 360 ml beers/45 ml liquor containing 40% alcohol/150 ml grape wine) 3 months prior to screening period, positive results of alcohol breath test and the volunteers who cannot give up drinking during study.

3. The participants who have overconsumption of tea, coffee, and the drink with caffeine (> 8 cup one day, 1 cup=250 ml) daily 3 months prior to screening period.

4. The participants have history of substance abuse and drug use within 6 months before screening.

5. The participants have history of chronic disease and serious illness in nervous system, vascular system, blood and lymphatic system, immune system, urinary system, respiratory system, digestive system and other metabolic system, any conditions and illness threat to the health of participants, and the history of hereditary disease.

6. The participants had a clinically significant disease, major surgery within 3 months before screening or plan surgery during the study period, and the surgery could affect drug absorption, distribution, metabolism, and excretion.

7. The participants who participated other clinical trials and took the investigational drug 3 months prior to first dose.

8. The participants who have blood donation or excessive bleeding (≥ 400 ml) 3 months prior to first dose, and planned to donate blood or receive blood transfusions.

9. The participants who were taking any prescription medicine, any over-the-counter (OTC), traditional chinese medicine and health care products within 14 days prior to screening period; CYP3A4 inducers/inhibitors within 30 days prior to screening period.

10. The participants who have eaten grapefruit, orange, mango, pitaya, chocolate, any caffeinated food or drink that affects the absorption, distribution, metabolism and excretion of the drug within 7 days before first dose.

11. The participants who cannot comply with the roles of unified diet.

12. The participants who have positive test result in HBsAg, antibodies against HCV (anti-HCV), Anti-HCV, Anti-HIV and TPPA.

13. The participants who cannot tolerate blood collection through venipuncture.

14. Any factors judged by investigator that the participants cannot meet.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

TYK Medicines, Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kunyan Li, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Hunan Provincial Tumor Hospital

Xue Chen, MD

Role: PRINCIPAL_INVESTIGATOR

Hunan Provincial Tumor Hospital

Locations

Hunan Provincial Tumor Hospital

Changsha, Hunan, China

Countries

China

Other Identifiers

TYKM1601102

Identifier Type: -

Identifier Source: org_study_id